IM Cannabis Corp.

IMCC Healthcare Drug Manufacturers Specialty & Generic

IM Cannabis Corp.’s revenue for fiscal 2025 (year ended December 2025) was $39.2 million, down 0.66% from fiscal 2024. In the quarter to June 2026, revenue fell 40.3%, EPS fell 385.7%, free cash flow fell 266.8% and total debt fell 64.7%, each against the same quarter a year earlier. Operating cash flow growth for three consecutive years.

1.36 0.03 +2.26%
Market cap
$2.2M
P/E
0.0×
Fwd P/E
0.0×
Dividend yield
—
F-score
4/9
Altman Z
−11.69
Beneish M
−5.42
Dividend safety
n/a
Older periods Sep '25 Dec '25 Mar '26 Jun '26
Piotroski F-Score

+8 more TTM periods

6 5 4 3
ROE
(107.89%) 5,562.03% 1,305.05% 2,280.06%
ROA
(10.32%) (31.58%) (40.98%) (54.20%)
ROIC
(86.01%) 0.00% 0.00% 0.00%
Return on Tangible Assets
155.22% 149.84% 152.29% 189.48%
Average Days of Receivables
79.58 72.35 51.83 54.63
Free Cash Flow per Share
(16.85) 24.18 0.60 (1.58)
Free Cash Flow
(2.73) 3.41 0.12 (0.49)
Other line items

Show all line items

Columns are period end dates